Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
Status:
Withdrawn
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This study is a prospective observational study in which patients undergoing treatment for
leishmaniasis with miltefosine (Impavido) in the US and who weigh > 75 kg can volunteer to
provide information about their clinical response to treatment up to 6 months after the start
of treatment.